What is your preferred regimen for triple positive breast cancer with visceral metastasis while on adjuvant AI?

My preferred regimen in this clinical situation would be to start with a taxane-based regimen plus trastuzumab and pertuzumab, per the CLEOPATRA trial. In this study, there is a highly significant and clinically meaningful overall survival advantage to adding pertuzumab in patients with newly metast...

I agree with @Dr. First Last that THP is typically the preferred 1st line strategy in patients with HER2+ disease of any HR status when visceral metastases are present. However, in patients with triple positive disease without visceral metastases one might consider other strategies. For example, in ...